Vandetanib
Sign in to save this workspacePrimary targets: KDR_VEGFR2 · FDA status: FDA Approved
Selectivity scorecard
KISS
95.74
Gini
0.723
CATDS
0.016
Computed from wild-type kinome inhibition at 1 μM. Gini reproduces the published values within tolerance; KISS and CATDS are computed but pending reconciliation with the paper's reference code.
Polypharmacology radar
Top 20 strongest-inhibited wild-type kinases for Vandetanib. Strongest target: EGFR at 99.3% inhibition.
Accessible data table
| Rank | Target | Inhibition % | Residual activity % |
|---|---|---|---|
| 1 | EGFR | 99.3% | 0.7% |
| 2 | LCK | 98.9% | 1.1% |
| 3 | RET | 98.6% | 1.4% |
| 4 | DDR2 | 98.5% | 1.5% |
| 5 | DDR1 | 98.5% | 1.5% |
| 6 | LYN | 98.0% | 2.0% |
| 7 | EPHA6 | 97.3% | 2.7% |
| 8 | ABL1 | 95.7% | 4.3% |
| 9 | BRK | 95.3% | 4.7% |
| 10 | YES_YES1 | 95.2% | 4.8% |
| 11 | FLT4_VEGFR3 | 94.8% | 5.2% |
| 12 | KDR_VEGFR2 | 94.5% | 5.5% |
| 13 | PEAK1 | 94.4% | 5.6% |
| 14 | C_SRC | 94.2% | 5.8% |
| 15 | LOK_STK10 | 93.8% | 6.2% |
| 16 | BLK | 92.8% | 7.2% |
| 17 | FGFR2 | 90.8% | 9.2% |
| 18 | ABL2_ARG | 89.0% | 11.0% |
| 19 | FLT1_VEGFR1 | 88.6% | 11.4% |
| 20 | EPHB1 | 88.1% | 11.9% |
Selectivity landscape
Where Vandetanib sits in the 92-drug selectivity landscape (KISS vs Gini). The highlighted point is Vandetanib.
Annotations
Sign in to read and post annotations.
Loading…